<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eighty-four patients with <z:hpo ids='HP_0001718'>mitral stenosis</z:hpo> and <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> have been followed up for 20 years </plain></SENT>
<SENT sid="1" pm="."><plain>Half of the series (those treated in the early years) had no <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> treatment and half were given long-term <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Mortality rate and causes of <z:hpo ids='HP_0011420'>death</z:hpo> have been reviewed, and comparison of survival times of treated and untreated groups by life-table analysis bears out the immediate need for <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> when a diagnosis of <z:mpath ids='MPATH_118'>systemic embolism</z:mpath> is established </plain></SENT>
<SENT sid="3" pm="."><plain>It is wise to continue the treatment for six months but it may be reasonable to discontinue it after one year with patients who can be assured of regular review </plain></SENT>
</text></document>